A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That
Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
